Skip to main content
Premium Trial:

Request an Annual Quote

Genetic Technologies Dismisses Patent Infringement Lawsuit against Agilent

NEW YORK (GenomeWeb) – Agilent Technologies said on Monday that Genetic Technologies has dismissed its lawsuit against the company alleging patent infringement.

In return, Agilent dismissed its counterclaims against Genetic Technologies of non-infringement and invalidity. No settlement was involved, Agilent said.

Genetic Technologies sued Agilent in 2011 claiming Agilent's Bioanalyzer, genomic hybridization microarrays, and GeneSpring software products infringed US Patent No. 5,612,179 owned by Genetic Technologies. The patents relates to methods of analyzing non-coding DNA sequences. Genetic Technologies, an Australian molecular diagnostics firm, has sued numerous companies in recent years alleging infringement of the '179 patent.

Agilent said that it has maintained that none of its products perform the methods claimed in the patent and that no Agilent customer has ever used the company's product to perform such methods. "Although Agilent respects valid, enforceable intellectual property rights of others, we will vigorously defend what we believe to be unfounded claims of infringement," Agilent Senior Vice President and General Counsel Marie Oh Huber said in a statement.

Earlier this year, the US District Court for the Northern District of California denied Agilent's motion to dismiss Genetic Technologies' lawsuit.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.